Halozyme Therapeutics Raises 2025 Guidance; Shares Up Pre-Bell

MT Newswires Live01-08 21:23

Halozyme Therapeutics (HALO) shares were 5% higher premarket Wednesday after the company raised its 2025 adjusted earnings per share and revenue guidance driven by higher royalty revenue and increased product sales from its Xyosted treatment.

The company now expects adjusted earnings per share for 2025 to range from $4.95 to $5.35, up from a previous forecast of $4.45 to $4.85. Analysts polled by FactSet expect full-year adjusted EPS of $4.83.

Halozyme also increased its full-year sales guidance to between $1.15 billion and $1.23 billion from a prior range of $1.1 billion to $1.17 billion. Analysts surveyed by FactSet expect full-year revenue of $1.16 billion.

For 2024, the company reiterated its adjusted earnings per share guidance of $4.00 to $4.20 and revenue guidance of $970 million to $1.02 billion. Analysts polled by FactSet expect 2024 adjusted EPS of $4.14 and revenue of $1 billion.

Halozyme also said it entered into a new $250 million accelerated share repurchase program that is part of a previously disclosed $750 million share repurchase initiative.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2501724019?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-08 21:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501724019","market":"sg","top_or_hot":-1,"title":"Halozyme Therapeutics Raises 2025 Guidance; Shares Up Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> Halozyme <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HALO) shares were 5% higher premarket Wednesday after the company raised its 2025 adjusted earnings per share and revenue guidance driven by higher royalty revenue and increased product sales from its Xyosted treatment.</p><p>The company now expects adjusted earnings per share for 2025 to range from $4.95 to $5.35, up from a previous forecast of $4.45 to $4.85. Analysts polled by FactSet expect full-year adjusted EPS of $4.83.</p><p>Halozyme also increased its full-year sales guidance to between $1.15 billion and $1.23 billion from a prior range of $1.1 billion to $1.17 billion. Analysts surveyed by FactSet expect full-year revenue of $1.16 billion.</p><p>For 2024, the company reiterated its adjusted earnings per share guidance of $4.00 to $4.20 and revenue guidance of $970 million to $1.02 billion. Analysts polled by FactSet expect 2024 adjusted EPS of $4.14 and revenue of $1 billion.</p><p>Halozyme also said it entered into a new $250 million accelerated share repurchase program that is part of a previously disclosed $750 million share repurchase initiative.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Halozyme Therapeutics Raises 2025 Guidance; Shares Up Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHalozyme Therapeutics Raises 2025 Guidance; Shares Up Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-08 21:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Halozyme Therapeutics (HALO) shares were 5% higher premarket Wednesday after the company raised its 2025 adjusted earnings per share and revenue guidance driven by higher royalty revenue and increased...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2501724019","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501724019","pubTimestamp":1736342626,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Halozyme Therapeutics  shares were 5% higher premarket Wednesday after the company raised its 2025 adjusted earnings per share and revenue guidance driven by higher royalty revenue and increased product sales from its Xyosted treatment.The company now expects adjusted earnings per share for 2025 to range from $4.95 to $5.35, up from a previous forecast of $4.45 to $4.85. Analysts polled by FactSet expect full-year adjusted EPS of $4.83.Halozyme also increased its full-year sales guidance to between $1.15 billion and $1.23 billion from a prior range of $1.1 billion to $1.17 billion. Analysts surveyed by FactSet expect full-year revenue of $1.16 billion.For 2024, the company reiterated its adjusted earnings per share guidance of $4.00 to $4.20 and revenue guidance of $970 million to $1.02 billion. Analysts polled by FactSet expect 2024 adjusted EPS of $4.14 and revenue of $1 billion.Halozyme also said it entered into a new $250 million accelerated share repurchase program that is part of","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","HALO":"奥洛兹美医疗","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)"},"translate_title":"Halozyme Therapeutics上调2025年指引；分享盘前","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HALO":1},"content_text":"Halozyme Therapeutics (HALO) shares were 5% higher premarket Wednesday after the company raised its 2025 adjusted earnings per share and revenue guidance driven by higher royalty revenue and increased product sales from its Xyosted treatment.The company now expects adjusted earnings per share for 2025 to range from $4.95 to $5.35, up from a previous forecast of $4.45 to $4.85. Analysts polled by FactSet expect full-year adjusted EPS of $4.83.Halozyme also increased its full-year sales guidance to between $1.15 billion and $1.23 billion from a prior range of $1.1 billion to $1.17 billion. Analysts surveyed by FactSet expect full-year revenue of $1.16 billion.For 2024, the company reiterated its adjusted earnings per share guidance of $4.00 to $4.20 and revenue guidance of $970 million to $1.02 billion. Analysts polled by FactSet expect 2024 adjusted EPS of $4.14 and revenue of $1 billion.Halozyme also said it entered into a new $250 million accelerated share repurchase program that is part of a previously disclosed $750 million share repurchase initiative.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2501724019"}